FDA Orange Book · active-ingredient family
Ferumoxytol
Ferumoxytol is approved as 2 brand and 1 generic application in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.
Reference-listed drug:FERABRIGHT · NDA 219868
2
Brand (NDA)
1
Generics (ANDA)
0
Listed patents
2
Exclusivity periods
Brand (NDA) products · solution
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| FERABRIGHTRLD×2 | AZURITY | NDA 219868 | — | Oct 16, 2025 | |
| FERAHEMERLD | AZURITY | NDA 022180 | AB | Jun 30, 2009 |
Generic (ANDA) products (1)
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| FERUMOXYTOL | SANDOZ | ANDA 206604 | AB | Jan 15, 2021 |
Marketing exclusivity (2)
- NPNew product exclusivity (3 years)
Oct 16, 2028
in 2 yr 4 mo
- NPNew product exclusivity (3 years)
Oct 16, 2028
in 2 yr 4 mo
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Ferumoxytol — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

